1Garc a-Velloso MJ,Jurado M,Ceamanos C,et al.Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma[J].Eur J Nucl Med Mol Imaging,2007,34:1396-1405.
2Elit L,Zitzelsberger L,Fung-Kee-Fung M,et al.Use of systemic therapy in women with recurrent ovarian cancer-development of a national clinical practice guideline[J].Gyneeol Oncd,2007,106:181-192.
3Salani R,Santillan A,Zahurak ML,et al.Secondary cytoreductive surgery for localized recurrent epithelial ovarian cancer[J].Cancer,2007,109(4):685-691.
4Tebos SJ,Sayer BA,Palmer JM,et al.Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma[J].Gynecol Oncol,2007,106:482-487.
5Perez-Gracia JL,Carrasco EM.Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings:systematic rcview of the literature and implications for future research[J].Gynecol Oncol,2002,84:201-209.
6Wilailak S,Linasmita V,Srisupundit S.Phase Ⅱ study of highdose megestrol acetate in platinum-refractory epithelial ovarian cancer[J].Anticancer Drugs,2001,12:719-724.
7Gnmdker C,Emons G.Role of gonadotropin-releasing hormone(GnRH)in ovarian cancer[J].Reprod Biol Endocrinol,2003,1:65-68.
8Verschraegen CF,Westphalen S,HuW,et al.Phase Ⅱstudy of cetrorelix,a Inteinizing hormone-releasing hormone antagonist in patient with platinum-resistant ovarian cancer[J].Gynecol Oncol,2003,90:552-559.
